Docetaxel
- PDF / 169,207 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 60 Downloads / 170 Views
1 S
Febrile neutropenia: case report In a retrospective review of 10 patients of breast cancer, who were treated between 2013 and 2017, a patient [age and sex not stated] was described, who developed febrile neutropenia during treatment with docetaxel for breast cancer. The patient, who had advanced breast cancer, started receiving IV docetaxel 50 mg/m2 given over 60 minutes. Docetaxel was administered on day 1 of a 2 week cycle. Concomitantly, the patient also started receiving dexamethasone, 1 day prior to docetaxel administration. However the patient developed febrile neutropenia, requiring hospital admission [duration of treatment to reaction onset not stated]. The patient further developed community-acquired pneumonia and eventually, died of respiratory failure. Lee DW, et al. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study. Medical Journal of Malaysia 75: 338-341, No. 4, Jul 2020. Available from: 803497788 URL: https://www.researchgate.net/publication/343319536_Two-weekly_docetaxel_in_treatment_of_advanced_breast_cancer_A_preliminary_study
0114-9954/20/1818-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 22 Aug 2020 No. 1818
Data Loading...
